Are Allergy Shots Subcutaneous or Intramuscular? The Clinical Rationale

The goals are opposite. Vaccines (flu, COVID, HPV) want rapid immune activation — fast antigen delivery to systemic circulation produces a quick, strong antibody response to create protective immunity. That is exactly what intramuscular injection delivers: muscle's dense blood supply rushes antigen into circulation within minutes. Allergy immunotherapy aims for the opposite: slow, long-term tolerance induction. Subcutaneous fat's lower vascularity causes gradual allergen release over hours, giving local tolerogenic dendritic cells time to capture allergen and program a regulatory rather than inflammatory immune response. If allergy shots were given IM, the rapid antigen surge could trigger systemic allergic reactions instead of building tolerance.

Accidental intramuscular injection can occur when using longer needles or in very lean patients where subcutaneous fat depth is minimal. The consequence is faster allergen absorption into systemic circulation — potentially increasing the risk and severity of a local or systemic allergic reaction compared to proper subcutaneous placement. This is one reason injection technique matters: assessing tissue depth and adjusting injection angle (typically 45 degrees in lean patients) ensures the needle reaches subcutaneous fat without penetrating the muscle fascia. With at-home SCIT through Curex, the prescribing allergist teaches this exact technique and supervises your first dose and every dose change live over Zoom, and a prescribed epinephrine auto-injector is confirmed on hand — because systemic reactions can occur even with correct technique, a brief self-observation after each injection is part of the protocol.

Early allergy injections, before the subcutaneous route was standardized in the mid-20th century, were occasionally administered intramuscularly. Historical accounts from the 1920s-1950s document IM administration before the immunological rationale for the SC route was fully understood (Gruber, Annals of Allergy 1955). As understanding of allergen absorption kinetics and dendritic cell biology developed, the field converged on subcutaneous as the safer and more effective route. By the time modern practice parameters were established, IM was effectively abandoned for allergy immunotherapy in all evidence-based guidelines.

No intramuscular allergy immunotherapy product is approved in the United States. Monoclonal antibodies like omalizumab (Xolair) and dupilumab (Dupixent) are injected subcutaneously, not intramuscularly. Biologic treatments for asthma such as mepolizumab (Nucala) are given subcutaneously as well. Epinephrine auto-injectors (EpiPen) for anaphylaxis are delivered intramuscularly, but that is emergency medication for rapid systemic effect, not an immunotherapy. The emerging investigational approach of intralymphatic immunotherapy (ILIT) bypasses both SC and IM routes by injecting directly into inguinal lymph nodes, but this is not commercially available.

The slower allergen absorption from subcutaneous fat is directly protective against systemic reactions. When allergen is released gradually, local mast cells and basophils can undergo progressive desensitization — a process shown to begin within the first 6 hours of build-up dosing (Novak et al., JACI 2012). Rapid IM absorption, by contrast, would deliver a bolus of allergen to systemic IgE-sensitized mast cells before local regulatory mechanisms can engage, increasing the probability of anaphylaxis. This is why the systemic reaction rate for standard SCIT (0.1% per injection) is considered low and manageable with the right safeguards — a prescribed epinephrine auto-injector confirmed on hand and a brief self-observation after each dose — whereas IM administration would likely produce unacceptably higher rates. Those same safeguards are what make eligible patients' at-home SCIT with Curex safe, alongside Zoom-supervised first and dose-change injections.

Intralymphatic immunotherapy (ILIT) is an investigational approach that bypasses both subcutaneous and intramuscular tissue by injecting allergen directly into inguinal (groin) lymph nodes under ultrasound guidance. Research by Senti et al. (PNAS 2008) found that just 3 total injections administered over 8 weeks produced immune tolerance changes comparable to years of conventional SCIT. The rationale is that lymph nodes already contain the T cell and dendritic cell populations needed for tolerance induction — delivering allergen there directly skips the dermal migration step. ILIT remains investigational and is not FDA-approved or widely available in the United States as of 2025.

Correct subcutaneous placement is essential for both efficacy and safety. If the injection consistently lands in muscle rather than subcutaneous fat, faster allergen absorption may increase reaction rates while potentially reducing the tolerogenic immune signaling that drives long-term benefit. The standard posterior upper arm site was chosen because it provides consistent subcutaneous tissue depth, is easily accessible for observation, and allows reliable needle placement. Site rotation between left and right arms across visits reduces cumulative local reaction burden and maintains consistent tissue depth at each injection location.